TABLE 2.
Demographics of French patients positive for SARS-CoV-2 used for the determination of Vidas SARS-CoV-2 IgM and IgG sensitivity (positive percent agreement with RT-PCR positivity)
| Vidas SARS-CoV-2 serology testing | IgM | IgG | Combined IgM/IgG |
|---|---|---|---|
| Patients with documented date of RT-PCR-positive test | |||
| No. of samples tested | 234 | 253 | 232 |
| Study population, n (%) | 132 (100) | 139 (100) | 130 (100) |
| Age in yrs, median (range) | |||
| Nonhospitalized (n = 61) | Missing | Missing | Missing |
| Other (n = 71/78/69) | 71 (27–96) | 70.5 (27–96) | 70 (27–96) |
| Gender, n (%) | |||
| Male | 47 (35.6) | 53 (38.1) | 47 (36.2) |
| Female | 24 (18.2) | 25 (18.0) | 22 (16.9) |
| Missing | 61 (46.2) | 61 (43.9) | 61 (46.9) |
| Disease severity, n (%) | |||
| Hospitalized | 56 (42.4) | 57 (41.0) | 54 (41.55) |
| Nonhospitalized | 61 (46.2) | 61 (43.9) | 61 (46.9) |
| Missing | 15 (11.4) | 21 (15.1) | 15 (11.55) |
| Patients with documented date of symptom onset | |||
| No. of samples tested | 108 | 113 | 105 |
| Study population, n (%) | 65 (100) | 71 (100) | 63 (100) |
| Age in yrs, median (range) | 70 (27–96) | 70 (27–96) | 70 (27–96) |
| Gender, n (%) | |||
| Male | 45 (69.2) | 51 (71.8) | 45 (71.4) |
| Female | 20 (30.8) | 20 (28.2) | 18 (28.6) |
| Disease severity, n (%) | |||
| Hospitalized | 50 (76.9) | 50 (70.4) | 48 (76.2) |
| Nonhospitalizeda | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 15 (23.1) | 21 (29.6) | 15 (23.8) |
a
Date of symptom onset not documented in nonhospitalized COVID-19 patients.